Navigation Links
Quest Diagnostics To Speak At The Oppenheimer 20th Annual Healthcare Conference
Date:11/2/2009

MADISON, N.J., Nov. 2 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Oppenheimer 20th Annual Healthcare Conference in New York City. The presentation is scheduled for Wednesday, November 4, 2009 at 11:25 a.m. Eastern Time.

During the conference, the company will reaffirm its 2009 guidance for revenue growth to approximate 3%, operating income to exceed 18% of revenues, and diluted earnings per share from continuing operations to range from $3.80 to $3.85.

The presentation will be webcast live during the conference and will be available to registered investors on the following site: http://www.veracast.com/webcasts/opco/healthcare09/75206492.cfm and to the public on www.QuestDiagnostics.com/investor. In addition, the archived webcast will be available one hour after the conclusion of the live event and will remain available until December 4, 2009.

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at www.QuestDiagnostics.com.

The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers and strategic partners and other factors discussed in "Business," in "Risk Factors," "Cautionary Factors that May Affect Future Results," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk" in the company's 2008 Annual Report on Form 10-K and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk" and "Risk Factors" in the company's 2009 Quarterly Reports on Form 10-Q and other items throughout the Form 10-K and the company's 2009 Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

    Contacts:
    Kathleen Valentine (Investors):   973-520-2900
    Wendy Bost (Media):               973-520-2800

SOURCE Quest Diagnostics


'/>"/>
SOURCE Quest Diagnostics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. For the First Time, Blood Donors May Answer Their Health History Questions Online From the Privacy of Their Home or Office
2. FDA Issues Another Emergency Use Authorization for Commercial H1N1 Flu Test to Quest Diagnostics Focus Diagnostics
3. Dynatronics Will Request Hearing With Nasdaq Regarding Listing Status
4. Quest Diagnostics Brings Genetic Testing for Plavix(R) Response to Coronary Stent Patients at Scripps Health
5. Stemedica Requests Pre-IND Meeting With FDA
6. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
7. Quest Diagnostics Introduces First Commercial Laboratory Test for Identifying the H1N1 Swine Flu Virus
8. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
9. Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State
10. ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
11. Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... Korea , Jan. 24, 2017 Mezzion ... in New Jersey State court alleging that Dr. Reddy,s ... in its Food and Drug Administration (FDA) cGMP practices, ... that Dr. Reddy,s repeatedly represented to Mezzion that it ... its misconduct from Mezzion.  The suit also states that ...
(Date:1/24/2017)... 2017 The global  active pharmaceutical ingredients (API) market ... based on a new report by Grand View Research, Inc. The rising ... the market over the forecast period. Advancements in recombinant molecular technologies and ... growth.  Continue Reading ... ...
(Date:1/24/2017)... January 24, 2017 Aptuit, LLC, ... Surgical Laboratory des Massachusetts General Hospital (MGH) unter Leitung ... es um die Identifizierung und Validierung neuartiger Targets in ... sie der Resistenz von Antibiotika bei der Behandlung schwerer ... ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... , ... Center for Hispanic Leadership (CHL) Academy , the talent development ... Employee & Labor Relations at City of Hope , a world-renowned independent research ... City of Hope is committed to stay out in front of its communities’ growing ...
(Date:1/24/2017)... Iowa City, IA (PRWEB) , ... January 24, 2017 , ... ... in the country, has taken great care to design a program that provides teachers ... language abroad and domestically. This online teaching certificate is ideal for post-baccalaureate students and ...
(Date:1/24/2017)... , ... January 24, 2017 , ... The NewKILO JRP, ... Institutes (NMIs) and co-funded by the European Union (EU), was completed in May 2015. ... vacuum, instead being maintained and used in air, which presents some challenges to establishing ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... water, has officially unveiled its latest award-winning bottles, designed specifically to optimize the ... , Taza Agua is renowned for introducing the world’s first untouched bottled ...
(Date:1/24/2017)... ... January 24, 2017 , ... “Speaking With God’s Voice”: a resolute ... the creation of published author, Louis A. Miraglia, a born-again believer, who spent his ... God’s great, impactful Word. , “There is little doubt that God Himself prepared ...
Breaking Medicine News(10 mins):